Skip to main content

Table 1 Serious adverse events

From: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes

Group (# subjects) All-cause Respiratory Gastrointestinal Cardiac
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
29 W (n = 15) 9 (16) 1 (1) 5 (9) 3 (5) 1 (1) 5 (8) 6 (7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
32 W (n = 15) 5 (14) 1 (1) 5 (9) 3 (5) 0 (0) 4 (6) 3 (4) 0 (0) 0 (0) 2 (2) 1 (1) 1 (1)
32 W-CFM (n = 16) 5 (9) 6 (9) 6 (8) 4 (4) 6 (6) 5 (6) 0 (0) 1 (1) 0 (0) 0 (0) 1 (1) 2 (2)
  1. Number of patients with a serious adverse event within the 29 W, 32 W and 32 W confirmation (32 W-CFM) groups. Values are # of patients, (# of events)
\